Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine-Related Disorders | 8 | 2020 | 202 | 2.710 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 3 | 2020 | 17 | 1.650 |
Why?
|
| Doxazosin | 3 | 2020 | 28 | 1.240 |
Why?
|
| Substance-Related Disorders | 5 | 2018 | 458 | 1.210 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 3 | 2020 | 18 | 0.740 |
Why?
|
| Psychiatry | 2 | 2015 | 263 | 0.690 |
Why?
|
| Addiction Medicine | 1 | 2018 | 3 | 0.610 |
Why?
|
| Self-Assessment | 1 | 2018 | 66 | 0.600 |
Why?
|
| Adolescent Behavior | 1 | 2018 | 171 | 0.530 |
Why?
|
| Disulfiram | 2 | 2013 | 34 | 0.520 |
Why?
|
| Cocaine | 2 | 2016 | 206 | 0.500 |
Why?
|
| Alcohol Deterrents | 2 | 2019 | 12 | 0.480 |
Why?
|
| Needs Assessment | 1 | 2015 | 173 | 0.440 |
Why?
|
| Drug Design | 1 | 2014 | 146 | 0.440 |
Why?
|
| Internship and Residency | 2 | 2015 | 1159 | 0.420 |
Why?
|
| Curriculum | 1 | 2018 | 718 | 0.410 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 352 | 0.400 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 1141 | 0.390 |
Why?
|
| Opioid-Related Disorders | 4 | 2016 | 257 | 0.390 |
Why?
|
| Double-Blind Method | 6 | 2020 | 1600 | 0.390 |
Why?
|
| Narcotic Antagonists | 3 | 2016 | 104 | 0.360 |
Why?
|
| Buprenorphine | 3 | 2016 | 92 | 0.360 |
Why?
|
| Data Collection | 1 | 2012 | 384 | 0.340 |
Why?
|
| Polymorphism, Genetic | 3 | 2020 | 807 | 0.340 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2019 | 624 | 0.330 |
Why?
|
| Pilot Projects | 3 | 2020 | 1390 | 0.310 |
Why?
|
| Genotype | 4 | 2020 | 2533 | 0.290 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2586 | 0.290 |
Why?
|
| Pharmacogenetics | 2 | 2020 | 183 | 0.270 |
Why?
|
| GABA Agents | 2 | 2019 | 21 | 0.260 |
Why?
|
| Dopamine beta-Hydroxylase | 2 | 2018 | 29 | 0.260 |
Why?
|
| Opiate Substitution Treatment | 2 | 2016 | 22 | 0.240 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 1084 | 0.180 |
Why?
|
| Vaccines | 2 | 2017 | 370 | 0.180 |
Why?
|
| Humans | 17 | 2020 | 123287 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1239 | 0.160 |
Why?
|
| Valproic Acid | 1 | 2019 | 164 | 0.150 |
Why?
|
| Adult | 6 | 2020 | 29087 | 0.150 |
Why?
|
| Alcoholism | 1 | 2019 | 230 | 0.140 |
Why?
|
| Female | 8 | 2020 | 65609 | 0.140 |
Why?
|
| Methadone | 2 | 2016 | 124 | 0.140 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2016 | 24 | 0.130 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 35 | 0.130 |
Why?
|
| Legislation, Medical | 1 | 2016 | 13 | 0.130 |
Why?
|
| Middle Aged | 6 | 2020 | 26074 | 0.130 |
Why?
|
| Drug Discovery | 1 | 2017 | 170 | 0.130 |
Why?
|
| Male | 8 | 2020 | 60276 | 0.130 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2015 | 25 | 0.130 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 143 | 0.130 |
Why?
|
| Educational Measurement | 1 | 2018 | 324 | 0.120 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 393 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 218 | 0.120 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2019 | 373 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2015 | 284 | 0.110 |
Why?
|
| Prescription Drugs | 1 | 2014 | 52 | 0.110 |
Why?
|
| Forecasting | 1 | 2015 | 354 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 507 | 0.110 |
Why?
|
| United States | 4 | 2019 | 10667 | 0.100 |
Why?
|
| Treatment Outcome | 5 | 2018 | 12167 | 0.100 |
Why?
|
| Berberine Alkaloids | 1 | 2011 | 2 | 0.100 |
Why?
|
| Dopamine Agonists | 1 | 2011 | 79 | 0.090 |
Why?
|
| Research Design | 1 | 2014 | 679 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 402 | 0.090 |
Why?
|
| Vaccination | 2 | 2014 | 947 | 0.090 |
Why?
|
| Global Health | 1 | 2014 | 546 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2014 | 658 | 0.080 |
Why?
|
| Alleles | 1 | 2013 | 1603 | 0.080 |
Why?
|
| Naltrexone | 2 | 2019 | 69 | 0.070 |
Why?
|
| Veterans | 1 | 2019 | 1735 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 3382 | 0.070 |
Why?
|
| Young Adult | 2 | 2016 | 8871 | 0.060 |
Why?
|
| Brain | 1 | 2015 | 2967 | 0.060 |
Why?
|
| Adolescent | 2 | 2018 | 19131 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2018 | 174 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 151 | 0.040 |
Why?
|
| Clonidine | 1 | 2016 | 35 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 1419 | 0.030 |
Why?
|
| Aged | 1 | 2013 | 19174 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1498 | 0.030 |
Why?
|
| Animals | 1 | 2014 | 33790 | 0.030 |
Why?
|
| Safety | 1 | 2014 | 218 | 0.030 |
Why?
|
| Antibodies | 1 | 2014 | 371 | 0.030 |
Why?
|